PREVENTION WITH DESORGESTREL OF ENDOMETRIOUS CYSTS RECURRENCE AFTER SURGICAL TREATMENT
Currently, endometriosis is an important public health issue due to the increasing number of cases and the risk of developing ovarian and endometrial tumours(10% of ovarian endometrial carcinomas are associated with uterine endometrioid carcinomas), which has led to increased research into the mechanisms of appearance and progression of this condition.Although endometriosis is considered a benign chronic disease, it can show an invasive character causing severe symptoms. Endometriosis has an increasing incidence, affecting 2% of the general population, being the third gynecological cause of infertility, chronic pelvic pain, dyspareunia and dysmenorrhea. Endometriosis affects 7-15% of women of childbearing age, with 25-30% of sterility cases having a significant social impact. Endometriomas are difficult to excise due to vascularization and increased adhesion of the cyst wall. Surgical treatment of endometriosis is effective in the short term. Surgery most often reduces ovarian reserve. The rate of recurrence after surgery can be reduced with the help of menstrual suppression medications such as hormonal contraceptives. Desogestrel treatment improves intraoperative conditions mainly by reducing bleeding and increasing laxity between cyst coat and normal ovarian tissue.
2. Aznaurova, Y.B., et al. (2014).Endometriosis.ReprodBiolEndocrin, 12: 50-74.
3. Giudice, L.C.(2010). Clinical practice. Endometriosis.N Engl J Med, 362: 2389-2398.
4. Verkauf, B.S.(1987). Incidence, symptoms and signs of endometriosis in fertile and infertile women. J Fla Med
Assoc, 74(9): 671-675.
5. Lucidi, R.S., Witz, C.A., Chrisco, M., et al.(2005). A novel in vitromodel of the early endometriotic lesion
demonstrated that attachment of endometrial cells to mesothelial cells is dependent on the source of endometrial
cells.Fertil. Steril, 84: 16-21.
6. Vercellini, P., Crosignani, C.G., Somigliana, G., et al. (2011). ‘Waiting for Godot’: a commonsense approach to
the medical treatment of endometriosis.Hum Reprod, 26(1): 3-13.
7. Peltecu, Gh.(2014). Treaty of surgery vol.V, Obstetrics and Gynecology, edited by IrinelPopescu, Constantin Ciuce,
Romanian Academy Publishing House. Chap 5: Endometriosis; C Ionescu, I Pacu. 53-73.
8. Bedaiwy, M.A., Falcone, T.(2004). Laboratory testing for endometriosis. ClinChimActa, 340:41-56.
9. Wu, M.Y., Chaok, H. (1996). The suppression of peritoneal cellular iminity in women with endometriosis could be
restored after gonadotropin releasing hormone agonist treatment. Am J Repr. Imunol, 35: 510.
10. Foda, A.A., Abdel Aal, I. A. (2012).Metformin as a new therapy for endometriosis, its effectson both clinical
picture and cytokines profile.Middle East Fertility Society.
11. Bedaiwy, M.A., Falcone, T., Sharma, R.K., et al. (2002).Prediction of endometriosis with serum and peritoneal
fluid markers: a prospective controlled trial. Hum Reprod, 17: 426-431.
12. Johnson, N.P., Hummelshoj, L. (2013).World. Endometriosis Society Montpellier Consortium. Consensus on
current management of endometriosis. Hum Reprod, 28(6): 1552-1568.
13. Barbieri, R.L., Niloff, J.M., Bast, R.C. Jr, et al. (1986).Elevated serum concentrations of CA-125 in patients with
advanced endometriosis. Fertil.Steril, 45: 630-634.
14. Pittaway, D.E., Douglas, J.W. (1989).Serum CA-125 in women with endometriosis and chronic pelvic pain. Ferti.
Steril, 51: 68-70.
15. Koyama, N., Matsuura, K., Okamura, H.(1993). Cytokines in the peritoneal fluid of patients with
endometriosis.Int J GynecolObstet, 43: 45-50.
16. May, K.E., Conduit-Hulbert, S.A., Villar, J., et al. (2010). Peripheral biomarkers of endometriosis: a systematic
review.Hum Reprod Update, 16: 651-674.
17. Burney, R.O., Giudice, L.C.(2012). Pathogenesis and patho-physiology of endometriosis.Fertil.Steril, 98: 511–
18. Streuli, I., Ziegler, D., Santulli, P., et al. (2013). An update on the pharmacological management of
endometriosis. Expert OpinPharmacother, 14: 291-305.
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. The journal allow readers to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose.
The Author is the sole copyright holder of the published article. The articles are distributed under the CC BY 4.0 license.
The authors are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits